BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 29, 2015
 |  BioCentury  |  Finance

Viehbacher navigates to Waypoint

Why Christopher Viehbacher joined Gurnet Point Capital

Although Christopher Viehbacher will take over life sciences fund Gurnet Point Capital at the all-time peak of biotech markets, the former Sanofi CEO still sees opportunities for investments and buyouts.

Gurnet was launched in 2013 as the first U.S. fund of Waypoint Capital, the investment vehicle of the Bertarelli family, which ran Serono S.A. until it sold its 64.5% stake in 2007 as part of Merck KGaA's (Xetra:MRK) CHF16.6 billion ($13.2 billion) acquisition of the Swiss company.

The fund will employ a hybrid venture/private equity model. Venture...

Read the full 438 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >